Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | UGT2B17 | O75795 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15532270 | 0.81 | CYP11B1 (0.46) | CYP11B1CYP11B2UGT2B17S1PR1EPAS1 | |
| SCHEMBL1508635 | 0.81 | CYP11B1 (0.46) | CYP11B1CYP11B2UGT2B17S1PR1EPAS1 | |
| SCHEMBL15532010 | 0.80 | CYP11B1 (0.42) | CYP11B1CYP11B2UGT2B17S1PR1 | |
| SCHEMBL9279331 | 0.80 | UGT2B17 (0.51) | CYP11B1CYP11B2HTR2AHTR2CUGT2B17 | |
| SCHEMBL17200153 | 0.77 | TRPM8 (0.40) | CYP11B1CYP11B2UGT2B17MAP3K14EPAS1 | |
| SCHEMBL21142833 | 0.77 | TRPM8 (0.40) | CYP11B1CYP11B2UGT2B17MAP3K14EPAS1 | |
| SCHEMBL15532208 | 0.77 | HTR2A (0.45) | HTR2AHTR2CUGT2B17MAP3K14EPAS1 | |
| SCHEMBL21142112 | 0.77 | HTR2A (0.45) | HTR2AHTR2CUGT2B17MAP3K14EPAS1 | |
| SCHEMBL29121861 | 0.74 | UGT2B17 (0.56) | HTR2AHTR2CUGT2B17MAP3K14EPAS1 | |
| SCHEMBL15287064 | 0.74 | UGT2B17 (0.36) | UGT2B17MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | US | disclosed |
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | US | disclosed |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-28 | — | — | US | disclosed |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-28 | — | — | US | disclosed |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-13 | — | — | US | disclosed |
| US-9949977-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9949978-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9949977-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9949977-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9949978-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| EP-3045456-A1 | BICYCLIC SUBSTITUTED URACILS AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2016-07-20 | — | — | EP | disclosed |
| EP-3045456-A1 | BICYCLIC SUBSTITUTED URACILS AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2016-07-20 | — | — | EP | disclosed |
| EP-2847190-B1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | Bayer Pharma AG (DE) | 2016-04-06 | — | — | EP | disclosed |
| EP-2847190-B1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | Bayer Pharma AG (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-20150148340-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| US-20150148340-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| US-20150148340-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| EP-2847190-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013167495-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-14 | — | — | WO | disclosed |
| US-20080262086-A1 | SUBSTITUTED ANTHRANILIC ACIDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262086-A1 | SUBSTITUTED ANTHRANILIC ACIDS | GLS, ASNS, REN | CYP11B1 13/4885CYP11B2 12/4885HTR2A 2773/4885 |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | UNG, UMPS, TYMP | CYP11B1 529/4885CYP11B2 406/4885HTR2A 3833/4885 |
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | CYP11B1 529/4885CYP11B2 406/4885HTR2A 3833/4885 |
| US-20150148340-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | CYP11B1 529/4885CYP11B2 406/4885HTR2A 3833/4885 |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | CYP11B1 529/4885CYP11B2 406/4885HTR2A 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.